Published in J Virol on January 01, 2000
Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev (2001) 2.06
Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion. EMBO J (2003) 1.93
Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol (2001) 1.45
Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection. Proc Natl Acad Sci U S A (2001) 1.37
The mouse "xenotropic" gammaretroviruses and their XPR1 receptor. Retrovirology (2010) 1.35
A point mutation in the binding subunit of a retroviral envelope protein arrests virus entry at hemifusion. J Virol (2004) 1.30
Molecular gymnastics at the herpesvirus surface. EMBO Rep (2006) 1.29
Receptor binding transforms the surface subunit of the mammalian C-type retrovirus envelope protein from an inhibitor to an activator of fusion. J Virol (2001) 1.19
Fusion-defective gibbon ape leukemia virus vectors can be rescued by homologous but not heterologous soluble envelope proteins. J Virol (2002) 1.16
Specificity in receptor usage by T-cell-tropic feline leukemia viruses: implications for the in vivo tropism of immunodeficiency-inducing variants. J Virol (2001) 1.15
HTLV-1 and -2 envelope SU subdomains and critical determinants in receptor binding. Retrovirology (2004) 1.12
Comprehensive mutational analysis of the Moloney murine leukemia virus envelope protein. J Virol (2001) 1.08
The fusion-controlling disulfide bond isomerase in retrovirus Env is triggered by protein destabilization. J Virol (2005) 1.07
Subtle mutational changes in the SU protein of a natural feline leukemia virus subgroup A isolate alter disease spectrum. J Virol (2005) 1.04
Protein transfer into human cells by VSV-G-induced nanovesicles. Mol Ther (2011) 1.04
Feline leukemia virus envelope sequences that affect T-cell tropism and syncytium formation are not part of known receptor-binding domains. J Virol (2000) 1.03
Structure and mechanism of a coreceptor for infection by a pathogenic feline retrovirus. J Virol (2003) 1.03
Host cell cathepsins potentiate Moloney murine leukemia virus infection. J Virol (2007) 1.02
Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis. J Virol (2003) 1.01
Intersubunit disulfide isomerization controls membrane fusion of human T-cell leukemia virus Env. J Virol (2008) 0.99
Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo. J Virol (2002) 0.98
A virus-virus interaction circumvents the virus receptor requirement for infection by pathogenic retroviruses. J Virol (2003) 0.96
Identification of a novel subgroup of Koala retrovirus from Koalas in Japanese zoos. J Virol (2013) 0.95
Separable mechanisms of attachment and cell uptake during retrovirus infection. J Virol (2000) 0.94
Functional characterization of the N termini of murine leukemia virus envelope proteins. J Virol (2001) 0.91
Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU. J Virol (2003) 0.89
Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein. J Virol (2000) 0.88
Murine leukemia viruses: objects and organisms. Adv Virol (2011) 0.87
Identification of the hASCT2-binding domain of the Env ERVWE1/syncytin-1 fusogenic glycoprotein. Retrovirology (2006) 0.87
Retroviruses 2004: review of the 2004 Cold Spring Harbor Retroviruses Conference. Retrovirology (2004) 0.87
Murine leukemia virus (MLV) replication monitored with fluorescent proteins. Virol J (2004) 0.86
Porcine endogenous retroviruses infect cells lacking cognate receptors by an alternative pathway: implications for retrovirus evolution and xenotransplantation. J Virol (2004) 0.84
Role of the mutation Q252R in activating membrane fusion in the murine leukemia virus surface envelope protein. J Virol (2003) 0.84
Genetic and biochemical analyses of receptor and cofactor determinants for T-cell-tropic feline leukemia virus infection. J Virol (2002) 0.83
G100R mutation within 4070A murine leukemia virus Env increases virus receptor binding, kinetics of entry, and viral transduction efficiency. J Virol (2003) 0.81
Involvement of the C-terminal disulfide-bonded loop of murine leukemia virus SU protein in a postbinding step critical for viral entry. J Virol (2005) 0.81
Naturally Occurring Polymorphisms of the Mouse Gammaretrovirus Receptors CAT-1 and XPR1 Alter Virus Tropism and Pathogenicity. Adv Virol (2011) 0.80
Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor. Virology (2006) 0.80
Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants. J Virol (2006) 0.80
G541R within the 4070A TM protein regulates fusion in murine leukemia viruses. J Virol (2003) 0.79
An aromatic side chain is required at residue 8 of SU for fusion of ecotropic murine leukemia virus. J Virol (2004) 0.78
Differential inhibitory effects of cyanovirin-N, griffithsin, and scytovirin on entry mediated by envelopes of gammaretroviruses and deltaretroviruses. J Virol (2013) 0.77
Dissection of gammaretroviral receptor function by using type III phosphate transporters as models. J Virol (2005) 0.77
Truncated MTA-1: a pitfall in ELISA-based immunoassay of HTLV-1 infection. J Biomed Biotechnol (2008) 0.75
Nucleotide sequence of Moloney murine leukaemia virus. Nature (1981) 24.82
Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface. Cell (1986) 5.19
High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol (1995) 4.59
Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic, and polytropic murine leukemia viruses. J Virol (1992) 4.58
Retrovirus envelope domain at 1.7 angstrom resolution. Nat Struct Biol (1996) 4.49
Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol (1990) 4.22
Sequence analysis of amphotropic and 10A1 murine leukemia viruses: close relationship to mink cell focus-inducing viruses. J Virol (1990) 3.77
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci U S A (1997) 3.57
Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution. Science (1997) 3.13
A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol (1990) 3.00
Virus receptors: binding, adhesion strengthening, and changes in viral structure. J Virol (1994) 2.92
Basis for receptor specificity of nonecotropic murine leukemia virus surface glycoprotein gp70SU. J Virol (1992) 2.61
Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells. J Virol (1998) 2.46
Functional dissection of the Moloney murine leukemia virus envelope protein gp70. J Virol (1997) 2.24
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J Virol (1999) 2.15
Analysis of the functional and host range-determining regions of the murine ectropic and amphotropic retrovirus envelope proteins. J Virol (1993) 2.12
Identification of a subdomain in the Moloney murine leukemia virus envelope protein involved in receptor binding. J Virol (1996) 2.12
Cell fusion induced by the murine leukemia virus envelope glycoprotein. J Virol (1993) 2.05
Plasma membrane receptors for ecotropic murine retroviruses require a limiting accessory factor. J Virol (1991) 2.05
A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol (1998) 1.89
Requirements for different components of the host cell cytoskeleton distinguish ecotropic murine leukemia virus entry via endocytosis from entry via surface fusion. J Virol (1997) 1.75
A point mutation in the env gene of a murine leukemia virus induces syncytium formation and neurologic disease. J Virol (1994) 1.65
Mechanisms of enveloped virus entry into animal cells. Adv Drug Deliv Rev (1998) 1.47
The envelope glycoprotein of an amphotropic murine retrovirus binds specifically to the cellular receptor/phosphate transporter of susceptible species. J Virol (1995) 1.43
Suppression of a fusion defect by second site mutations in the ecotropic murine leukemia virus surface protein. J Virol (1999) 1.35
Disulfide bonding controls the processing of retroviral envelope glycoproteins. J Biol Chem (1991) 1.27
Receptor-binding properties of a purified fragment of the 4070A amphotropic murine leukemia virus envelope glycoprotein. J Virol (1996) 1.26
Functional domains in the retroviral transmembrane protein. J Virol (1998) 1.21
Functional interactions between monomers of the retroviral envelope protein complex. J Virol (1997) 1.17
Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15E. J Virol (1998) 1.15
Evidence for cooperation between murine leukemia virus Env molecules in mixed oligomers. J Virol (1998) 1.10
Modifying the host range properties of retroviral vectors. J Gene Med (2000) 1.08
Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding. EMBO J (1997) 1.07
Exceptional fusogenicity of Chinese hamster ovary cells with murine retroviruses suggests roles for cellular factor(s) and receptor clusters in the membrane fusion process. J Virol (1996) 1.02
Modulation of phosphate uptake and amphotropic murine leukemia virus entry by posttranslational modifications of PIT-2. J Virol (1999) 0.99
An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor. J Virol (2000) 4.05
Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther (2000) 2.95
Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol (1992) 2.50
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol (1995) 2.36
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. Neurology (2009) 2.33
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet (1986) 2.04
A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol (1998) 1.89
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol (1994) 1.83
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 1.82
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 1.67
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant (2007) 1.56
Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest (1994) 1.54
The epidemiology of dog walking: an unmet need for human and canine health. Med J Aust (2002) 1.53
Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature (1996) 1.46
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther (2010) 1.44
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther (2006) 1.43
Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol (2000) 1.40
Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum Gene Ther (1996) 1.37
The 19S complex of the proteasome regulates nucleotide excision repair in yeast. Genes Dev (2001) 1.36
Polyploidy, phylogeography and Pleistocene refugia of the rockfern Asplenium ceterach: evidence from chloroplast DNA. Mol Ecol (2002) 1.36
Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol (2001) 1.31
Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol (1996) 1.30
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res (2000) 1.24
Discovery of antibodies. BMJ (1992) 1.24
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther (2012) 1.24
Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells. J Virol (1998) 1.22
Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol (2001) 1.20
Curative one-shot systemic virotherapy in murine myeloma. Leukemia (2012) 1.20
Targeting retrovirus entry. Gene Ther (1996) 1.19
Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol (2003) 1.19
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther (2008) 1.18
Targeting of retroviral vectors through protease-substrate interactions. Gene Ther (1996) 1.15
Glycoprotein folding in the endoplasmic reticulum: a tale of three chaperones? FEBS Lett (2000) 1.15
Definition of an amino-terminal domain of the human T-cell leukemia virus type 1 envelope surface unit that extends the fusogenic range of an ecotropic murine leukemia virus. J Biol Chem (2000) 1.12
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther (2012) 1.12
Detection of two antigenic subpopulations of A(H1N1) influenza viruses from pigs: antigenic drift or interspecies transmission? J Med Virol (1991) 1.12
Lentiviral vectors derived from simian immunodeficiency virus. Curr Top Microbiol Immunol (2002) 1.09
Antigenic and sequence analysis of H3 influenza virus haemagglutinins from pigs in Italy. J Gen Virol (1994) 1.09
Modifying the host range properties of retroviral vectors. J Gene Med (2000) 1.08
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther (2001) 1.07
Goats' milk quackery. J Paediatr Child Health (2005) 1.07
Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding. EMBO J (1997) 1.07
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther (2006) 1.07
Myocardial injury-induced fibroblast proliferation facilitates retroviral-mediated gene transfer to the rat heart in vivo. J Gene Med (2000) 1.07
Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biol (2007) 1.06
Retroviral vectors pseudotyped with lymphocytic choriomeningitis virus. J Virol (1999) 1.05
Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther (2002) 1.05
Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol (2001) 1.04
Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther (2001) 1.04
Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther (1996) 1.03
Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J Virol (1998) 1.03
TM domain swapping of murine leukemia virus and human T-cell leukemia virus envelopes confers different infectious abilities despite similar incorporation into virions. J Virol (1996) 1.02
Genetic discontinuity, breeding-system change and population history of Arabis alpina in the Italian Peninsula and adjacent Alps. Mol Ecol (2008) 1.02
Cancer gene therapy: hard lessons and new courses. Gene Ther (2000) 1.01
CXC chemokines interleukin-8 (IL-8) and growth-related gene product alpha (GROalpha) modulate Purkinje neuron activity in mouse cerebellum. J Neuroimmunol (1998) 1.01
Generation of a helper cell line for packaging avian leukosis virus-based vectors. J Virol (1989) 1.01
Importance of 3' non-coding sequences for efficient retrovirus-mediated gene transfer in avian cells revealed by self-inactivating vectors. J Gen Virol (1993) 1.00
Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother (2001) 0.99
A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther (2000) 0.99
Measles virus as an oncolytic vector platform. Curr Gene Ther (2008) 0.98
The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J Mol Biol (1993) 0.98
In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol (1998) 0.97
Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther (1999) 0.97
Synthesis, assembly, and processing of the Env ERVWE1/syncytin human endogenous retroviral envelope. J Virol (2005) 0.96
Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther (2011) 0.95
Optimized gene transfer into human primary leukemic T cell with NOD-SCID/leukemia-initiating cell activity. Leukemia (2009) 0.93
Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther (2009) 0.93
Amiodarone induced skin necrosis. Heart (2006) 0.93
Genetic diversity and phylogeography in two diploid ferns, Asplenium fontanum subsp. fontanum and A. petrarchae subsp. bivalens, in the western Mediterranean. Mol Ecol (2009) 0.92
Defective retroviral endogenous RNA is efficiently transmitted by infectious particles produced on an avian retroviral vector packaging cell line. Virology (1995) 0.92
Retroviruses as vectors. Br Med Bull (1995) 0.91
Recombination diversifies chloroplast trnF pseudogenes in Arabidopsis lyrata. J Evol Biol (2007) 0.91
Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther (1999) 0.91
Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood (1998) 0.90
Familial clustering of scleroderma spectrum disease. Am J Med (1988) 0.90
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther (2013) 0.90